Ustekinumab is an IL-12/IL-23 inhibitor that works differently from TNF-inhibitors like Adalimumab, making it a key second-line option when those drugs stop working for a patient.
- Approved indications: Moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis
- Mechanism: Blocks IL-12 and IL-23, two proteins that drive inflammation in autoimmune skin and bowel disease
- Typical use case: Second-line therapy after TNF-inhibitor treatment fails or loses effectiveness
- Dosing format: Subcutaneous injection — less infrastructure-dependent than IV-infusion biologics
Because Ustekinumab suppresses part of the immune system, screening and monitoring are essential before and during treatment.
- Pre-treatment requirement: Active tuberculosis screening mandatory
- Vaccination: Live vaccines should be avoided during treatment
- Caution population: Patients with a history of malignancy
- Pregnancy: Use only after specialist evaluation
We source Ustekinumab through the same rigorous manufacturer-vetting process we apply across our biologics portfolio, so buyers get consistent quality regardless of which product they're ordering from us.
- Certification: WHO-GMP certified manufacturing partners
- Batch testing: IL-12/23 binding potency validated per batch
- Pre-export check: Certification status matched against destination-country accepted accreditation list before quoting
Every order comes with the core documentation set international customs and drug authorities require for import clearance.
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
| WHO-GMP / country-specific certification |
On request |
Stock status: Available on request | Quote turnaround: Confirm strength, quantity, and destination for pricing
Ustekinumab ships under the same cold-chain discipline we apply to every biologic in our catalogue, since a break in temperature control can compromise the product before it reaches the patient.
- Logistics: GDP-compliant cold chain export
- Active corridors: LATAM, Africa, GCC, Southeast Asia
- Shipment support: Full tracking and customs-documentation assistance
For markets where Ustekinumab isn't yet locally registered, we help buyers navigate the import process rather than leaving them to source it independently.
- Institutional buyers: Hospital and pharmacy distributor procurement support
- Unregistered markets: Named-patient supply available
- Portfolio fit: Complements existing TNF-inhibitor lines (Adalimumab, Infliximab) for distributors building a full immunotherapy range
What is Ustekinumab used for?
Treats moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease/ulcerative colitis.
Get Ustekinumab price from a GMP-compliant Indian supplier — how?
Send strength, quantity, and destination for a verified export quote.
Is it used when TNF-inhibitors like Adalimumab fail?
Yes, it's commonly prescribed as a second-line option after TNF-inhibitor therapy stops working.
Who supplies Ustekinumab from India?
WHO-GMP certified manufacturing partners with full export documentation.
Does it require cold chain shipping?
Yes, it must be stored and transported at 2–8°C throughout the supply chain.
